Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Articles online first > Minerva Gastroenterology 2021 May 10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Gastroenterology 2021 May 10

DOI: 10.23736/S2724-5985.21.02875-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Impact of Direct-Acting Antivirals (daas) on cardiovascular diseases in patients with chronic hepatitis C

Grazia PENNISI 1 , Federica SPATOLA 1, Lorenza DI MARCO 2, Vincenzo DI MARTINO 1, Vito DI MARCO 1

1 Section of Gastroenterology and Hepatology, Dipartimento Di Promozione Della Salute, Materno Infantile, Medicina Interna e Specialistica Di Eccellenza (PROMISE), University of Palermo, Palermo, Italy; 2 Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia, Modena, Italy


PDF


In the last years the hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection. Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogenic effect of the virus. This review aims to explore the evidence linking HCV infection with cardiovascular disease and to evaluate the impact of SVR after DAAs on cardiovascular complications.


KEY WORDS: HCV, chronic C hepatitis; CVD, cardiovascular diseases; DAAs, direct antiviral agents

inizio pagina